Back to results
US 2026/0199376 A1Published application
Pharmaceutical combination and use thereof
AssigneesAscentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
InventorsYifan ZHAI, Dajun YANG, Douglas Dong FANG, Guangfeng WANG, Jing DENG, Qiuqiong TANG, Ran TAO
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.
Claims21
-108. (canceled)
A combination comprising:
- a) a first compound, wherein the first compound is
- or a pharmaceutically acceptable salt thereof;
- and
- b) a second compound, wherein the second compound is a FLT3 inhibitor, a CDK4/6 inhibitor, a PI3K inhibitor, an MCL-1 inhibitor, a JAK2 inhibitor, an EGFR inhibitor, CDK9 inhibitor, a HER2 inhibitor, an anti PD-1 antibody, an anti-PD-L1 antibody, bortezomib, lenalidomide, pomalodomide, dexamethasone, cytarabine, tamoxifen, a hypomethylating agent,
- or a pharmaceutically acceptable salt thereof.
2 more elements
A method of treating a cancer in a subject in need thereof, comprising administering to the subject:
- a first compound, wherein the first compound is
- or a pharmaceutically acceptable salt thereof;
- and
- b) a second compound, wherein the second compound is a FLT3 inhibitor, a CDK4/6 inhibitor, a PI3K inhibitor, an MCL-1 inhibitor, a JAK2 inhibitor, an EGFR inhibitor, CDK9 inhibitor, a HER2 inhibitor, an anti PD-1 antibody, an anti-PD-L1 antibody, bortezomib, lenalidomide, pomalodomide, dexamethasone, cytarabine, tamoxifen, a hypomethylating agent,
- or a pharmaceutically acceptable salt thereof.
2 more elements
Dependencies are inferred from the claim text.